| LP412299-2 | Body disposition facility address | COMPONENT | 1 |
| LP412300-8 | Funeral service licensee or other agent assuming custody of the body of the deceased | COMPONENT | 1 |
| LP412301-6 | Funeral service licensee identifier | COMPONENT | 1 |
| LP412302-4 | Limited Views for therapy or embolization or infusion | COMPONENT | |
| LP412306-5 | Medical records in response to authorization denial | COMPONENT | 1 |
| LP412307-3 | 2-Hydroxyethylflurazepam | COMPONENT | 2 |
| LP412308-1 | Alpha hydroxyalprazolam glucuronide | COMPONENT | 1 |
| LP412317-2 | Water deprivation challenge panel | COMPONENT | 1 |
| LP412318-0 | Vasopressin challenge post water deprivation panel | COMPONENT | 1 |
| LP412323-0 | Vasopressin | CHALLENGE | |
| LP412324-8 | Carbohydrate | CHALLENGE | |
| LP412350-3 | Bacterial embB gene drug resistance mutation | COMPONENT | 1 |
| LP412351-1 | Wound, Ostomy, and Continence Care | Document.SubjectMatterDomain | 12 |
| LP412352-9 | UGT1A1 gene full mutation analysis | COMPONENT | 1 |
| LP412353-7 | TYMP gene targeted mutation analysis | COMPONENT | 1 |
| LP412354-5 | MYCN gene copy number/nucleus | COMPONENT | 1 |
| LP412355-2 | MDM2 gene copy number/Chromosome 12 copy number | COMPONENT | 1 |
| LP412356-0 | Chromosome region 22q11.2 deletion+duplication | COMPONENT | 2 |
| LP412357-8 | SERPINC1 gene full mutation analysis | COMPONENT | 1 |
| LP412358-6 | 1p chromosome deletion/1q chromosome deletion | COMPONENT | 1 |
| LP412359-4 | F9 gene full mutation analysis | COMPONENT | 1 |
| LP412360-2 | MYCN gene copy number/Chromosome 2 copy number | COMPONENT | 1 |
| LP412361-0 | Chromosome 2 copy number/nucleus | COMPONENT | 1 |
| LP412362-8 | Chromosome 12 copy number/nucleus | COMPONENT | 1 |
| LP412363-6 | 19q chromosome deletion/19p chromosome deletion | COMPONENT | 1 |
| LP415691-7 | C-SSRS.PCI | METHOD | 4 |
| LP415693-3 | Volume.residual/Predicted | COMPONENT | 1 |
| LP415694-1 | Volume.expired per minute/Carbon dioxide production | COMPONENT | |
| LP415695-8 | Oxygen consumption/body weight | COMPONENT | |
| LP415696-6 | SURVEY.CSSRS | CLASS | |
| LP415697-4 | PANEL.SURVEY.CSSRS | CLASS | |
| LP415698-2 | Ventilatory equivalent for carbon dioxide^W exercise | COMPONENT | 1 |
| LP415702-2 | Volume.expired per minute/Carbon dioxide production^W exercise | COMPONENT | 1 |
| LP415703-0 | Genetics | CLASS | |
| LP415704-8 | InfectiousDisease | CLASS | |
| LP415705-5 | Hematology | CLASS | |
| LP415706-3 | Hepatology | CLASS | |
| LP415707-1 | Occupational Therapy | CLASS | |
| LP415708-9 | Orthopedics | CLASS | |
| LP415709-7 | Otolaryngology | CLASS | |
| LP415710-5 | Rheumatology | CLASS | |
| LP415724-6 | Fistula^W contrast IA & Guidance for percutaneous transluminal angioplasty + transcatheter placement of stent | COMPONENT | |
| LP415725-3 | Views limited for therapy or embolization or infusion^W contrast via existing catheter | COMPONENT | 1 |
| LP415726-1 | HEDIS 2020 Value Sets | COMPONENT | 1 |
| LP415727-9 | HEDIS 2020 Value Set - BMI percentile | COMPONENT | 1 |
| LP415728-7 | HEDIS 2020 Value Set - BMI | COMPONENT | 1 |
| LP415729-5 | HEDIS 2020 Value Set - CT Colonography | COMPONENT | 1 |
| LP415730-3 | HEDIS 2020 Value Set - Mammography | COMPONENT | 1 |
| LP415731-1 | HEDIS 2020 Value Set - Urine Protein Tests | COMPONENT | 1 |
| LP416102-4 | Views for dialysis fistula^W contrast IA & Guidance for percutaneous transluminal angioplasty + transcatheter placement of stent | COMPONENT | 1 |